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Abstract
Noroviruses are a common cause of gastroenteritis worldwide, but outbreaks appear to be more common in industrialized
countries than in developing countries, possibly reflecting differences in exposure and immunity. In this study, age-stratified
sera from India and UK populations were analysed for the presence of norovirus-genogroup II specific IgG by a time
resolved immunofluorescence assay and relative levels of antibodies in the two populations were compared. Antibody
levels were higher among all age groups in India than in UK and increased with age in India, whereas in the UK, levels of
antibody decreased in adulthood. These results indicate different patterns of exposure to noroviruses in the two countries.
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Introduction
Noroviruses (NoV) are a major cause of sporadic gastroenteritis
worldwide, as well as of outbreaks in hospitals and semi-closed
communities such as residential and nursing homes [1–2]. Trans-
mission is mainly via the fecal-oral route, through person-to-person
contact or throughcontaminated food,wateror the environment [3].
Infection elicits incomplete and short lived immunity, and previous
studies with volunteers demonstrated that although pre-existing
serum antibodies to NoV do not protect from re-infection, antibody
levels to NoV are associated with protection after repeated exposure
[4]. Seroprevalence studies have demonstrated that NoV infections
are ubiquitous and infections occur early in life with prevalence
reaching.95% in adults [5–7].
Reports of NoV prevalence in India are primarily from hospital
andcommunitybased studiesof sporadicacutegastroenteritis [8–11]
andonlyoneoutbreak ina semi-closed settinghasbeenreported [12].
This study examined the levels of humanNoV-specific antibodies
in age-stratified sera from India andUKpopulations as ameasure of
exposure toNoVinfections inthetwopopulations throughout lifeand
demonstrated adifferencewhichmay, at least in part, explain the low
incidence of NoV outbreaks in India in comparison to the UK.
Materials and Methods
Ethics Statement
The study was approved by the Institutional Review Boards of
the Christian Medical College, Vellore, India. Prior to enrollment,
written informed consent was obtained from the parents or legal
guardians of eligible children.
Study Area and Population
In India, 1044 sera included sera collected in a probability
proportional to size cluster survey conducted in Vellore from
August 1999 to February 2000 [13] (samples from 0–40 years),
and sera from the Biochemistry laboratory and the Community
Health and Development Hospital, Vellore from residents in
geographic areas of the serosurvey (sera from .40 years of age).
The studies were approved by the Institutional Review Board of
the Christian Medical College, Vellore. In the UK, 1034 sera
collected in 2000 or 2005 from the HPA Seroepidemiology
Programme (http://www.hpa.org.uk/webw/
HPAweb&Page&HPAwebAutoListName/Page/
1158313434390?p= 1158313434390) were used. Sera from both
cohorts were distributed in 5 age groups (Table 1).
Time Resolved Fluorescence Immunoassay (TRFIA)
Detection of human NoV-specific serum IgG was done by Time
Resolved Fluorescence Immunoassay (TRFIA), which incorpo-
rates lanthanide labels that confer high sensitivity and a wider
dynamic range than ELISA assays [14], and hence allows
quantitation without the need for inclusion of a dilution series.
Human NoV virus like particles (VLPs) were produced from an
epidemic strain GII.4v2 [15], circulating in the UK during 2002
and later detected worldwide, the viral protein 1 (VP1) has 94%
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amino acid homology to the predominant Indian strain. The VLPs
were used at a concentration of 2 mg/ml in 0.05 M carbonate/
bicarbonate buffer, pH 9.6 to coat 96-well high-binding microwell
plates (Costar, Corning, N.Y.), overnight at 4uC. Plates were
washed 5 times with DELFIA wash buffer (PerkinElmer, UK) and
100 ml of serum diluted 1:100 in DELFIA assay buffer
(PerkinElmer, UK) was loaded per test well. Each plate included
a standard curve of 8 serial two-fold dilution of a positive serum
sample starting at 1:100, a blank (no serum) and positive control
and a negative control (goat serum). The plates were incubated in
a humid chamber for 2 h at 37uC and then washed 5 times. A total
of 100 ml of europium (Eu) labelled anti-human IgG conjugate
(PerkinElmer, UK) diluted 1:500 in DELFIA buffer was added to
each well using a multi-channel pipette, followed by incubation for
1 h at 37uC and washing as before. A total of 150 ml of DELFIA
enhancement solution (PerkinElmer, UK) was added to each well
and plates were incubated in the dark at room temperature for
15 min with gentle rotation. Plates were read using a DELFIA
1234 reader (PerkinElmer, UK) and data analyzed using Multicalc
software, version 4.0 (Wallac Oy, Finland). The distribution of the
Eu counts was normalized by performing a natural log trans-
formation. The plate-to-plate variability between the assays was
eliminated by standardizing the slope and intercept across all
experimental runs of the log-transformed europium counts, against
a reference plate. Data were further analysed using STATA 10.0
for Windows (STATA Corp., TX, USA), using student’s t-test and
ANOVA, as appropriate.
Results and Discussion
Using a cut-off of +3SD above the mean of negative controls,
the prevalence of human NoV-specific antibody in both cohorts
was high, 99.5% and 99.4% in the India and the UK cohort,
respectively. With a higher arbitrary Eu count cut-off of 7000, 4%
of samples from UK and 1.6% samples from India were below this
cut-off, mainly in the 0–5 year age group, with younger children
within the group having fewer antibodies. The high prevalence
found in this study, particularly for the UK cohort, when
compared to previous studies may be due to the use of a more
sensitive assay and also the choice of antigen, which used the
recently widely circulating GII.4 strain, although a subset of sera
were evaluated with a GII.4 VLP made with a pre-2002 strain also
showed complete cross-reactivity (data not shown). Other studies
have shown that the antibodies detected in human NoV-specific
Table 1. Summary of sera tested.
Age Group India Cohort UK Cohort
,6 months 83 47
7 m–5 y 170 160
10–15 y 237 207
20–30 y 189 207
40–45 y 158 206
50–60 y 207 207
Total 1044 1034
doi:10.1371/journal.pone.0056239.t001
Figure 1. Distribution of Europium counts obtained with sera from the India and UK sera cohorts. The europium counts were log
transformed for a normal distribution. The first plate from India was the reference category and a slope and intercept was calculated for all other
plates from both India and the UK. The slope and the intercept values were used to standardize the log-transformed europium counts across
experimental runs. Standardized log-transformed values were then used for all analyses.
doi:10.1371/journal.pone.0056239.g001
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EIA are largely cross-reactive across different NoV genotypes [16–
19]. Studies examining seroprevalence to GII NoVs reported
overall seropositivity of 91.2%, 74.1% 87% and 96.5% in Italy,
France, Japan and South Africa, respectively [20–23] using
conventional ELISAs. A study from China showed that the
seropositivity increased from 70% among one year olds to 98%
among 8–9 year old children for human norovirus GII and from
65% in the one year olds to 100% among the 8–9 year old
children for human norovirus GI [24].
Although the proportion of seropositives to human NoV
antibody was comparable in the two populations, the levels of
antibodies as represented by the distribution of Eu counts were
markedly different (Figure 1). Due to the lack of a standard serum
for quatification of human NoV-specific antibodies, the results are
presented as relative quantitation of antibody levels between the
two cohorts rather than absolute quantification.
For the comparative analysis between the two cohorts, exclusion
of the negative samples did not alter the results, and data shown
includes the complete cohorts. Sera from India showed signifi-
cantly higher levels of norovirus-specific IgG than the sera from
UK across all 5 age groups (Fig. 2). The Indian panel showed
a steady rise in human NoV-specific antibody levels with age,
reaching the highest levels in the age group of 50–60 years of age
(Fig. 2). In the UK panel, the antibody levels was lowest among the
0–5 year old children with a mean (SD) log normalized Eu count
of 11.5 (1.8), increasing to 11.8 (1.3) in 10–15 years age group; the
differences were not statistically significant (P = 0.264). Among the
Indian samples, antibody levels were significantly different across
age groups, with higher levels among the 50–60 year age group
[Mean (SD) 12.6 (1.1)] in comparison to the younger age groups
0–5 [Mean (SD) 12.2(1.5), P = 0.003] and 10–15 year age groups
[Mean (SD) 12.2(1.5), P,0.001]. No significant difference was
observed (at p= 0.003 level, after Bonferroni correction) for any of
the other age groups (Fig. 2). The antibody levels were comparable
between males and females for all age groups except the 20–30
year olds. In this age group the antibody levels were higher in
females (12.1, 1.4) than in males (11.8, 1.4, P=0.016). Although
not statistically significant, this relationship held true for both India
[12.4 (1.5) vs. 12.0 (1.5), P=0.102] and UK [11.8 (1.3) vs. 11.6
(1.3), P=0.188] panels (data not shown).
The results show higher levels of human NoV-specific
antibodies in the population in India compared to the UK, with
the widest difference between the two populations in the youngest
and the oldest age groups analysed. These findings suggest more
constant exposure to noroviruses across all age groups in India
when compared to the UK. A number of factors are known to play
a role in the increased prevalence of some infectious diseases in
developing countries. These include poor hygiene and sanitation,
less access to healthcare, overcrowding as well as socio-cultural
differences wherein people in India live in larger family units when
compared to developed countries [25–28]. Norovirus infections,
similar to rotavirus infections, are endemic in infants and children.
Recently it has been demonstrated that in India, first rotavirus
infections occur earlier than in the middle and high-income
Figure 2. Distribution of log normalized Europium counts among the different age strata in India and the UK. The dots in the center
represent the mean Europium counts for that age group whereas the horizontal error bars represent +2 standard deviations. Europium counts were
measured by time resolved immunofluresecence assay.
doi:10.1371/journal.pone.0056239.g002
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countries, and that number of reinfections is higher [29] and that
seroprevalence of rotavirus group A antibodies is 100% in the
same age-stratified population as evaluated here [30]. The same
pattern could be expected for human norovirus infections, which
would be consistent with the data presented here and with other
studies from developing countries [23–24,31]. In the UK, the peak
of human norovirus-specific antibody levels in the 5–10 year olds is
likely to reflect increased opportunities for infection through
contact with other children. Indeed, in Europe, social contact rates
are highest in school age children [32]. The lower human
norovirus–specific antibody levels in the .50 years old could also
correlate with the increased susceptibility in this age group that
translates into the high frequency of norovirus outbreaks that are
seen each winter in the UK, particularly among elderly patients in
hospitals and residential care institutions. In addition to the social
contact across all ages, it is likely that in India there are also
greater opportunities for food, water and environmental trans-
mission of noroviruses, contributing to greater and steady
exposure and boosting of immunity. This may result in re-
infections being mostly subclinical, and outbreaks being rare in this
population in contrast to the high incidence of outbreaks involving
adults and the elderly in the UK and other high income countries.
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